TEXT OF STORY
STEVE CHIOTAKIS: The French pharmaceutical giant Sanofi-Aventis will pay $20 billion for Genzyme, that’s an American biotech firm based in Massachusetts.
The BBC’s Jon Bithrey is in London. He has more on this mega-deal that’s sure to make some waves. Hi Jon.
JON BITHREY: Hello Steve.
CHIOTAKIS: Now why has this French firm picked up Genzyme? What do they want with Genzyme?
BITHREY: Well Sanofi-Aventis is France’s biggest drug maker and it’s been after Genzyme for a while. Largely because Sanofi doesn’t have many new drugs of its own in the pipeline and it’s facing competition from generic producers. Genzyme makes a lot of treatments for rare diseases. Its best selling drug Cerezyme treats liver and neurological problems. It’s also producing a new range of drugs for high cholesterol.
CHIOTAKIS: $20 billion, Jon, is a lot of money. Is this a good deal for Sanofi?
BITHREY: Well not as good as it would have liked. It launched a hostile bid last September for $18.5 billion. That failed and it’s had to up that to more than $20 billion to get the board to agree. But Genzyme did have some production glitches of its best selling drugs a couple of years back and that pulled down its value, making it more vulnerable to a takeover. But this is still the biggest deal in the drug industry since Merck bought Schering Plough in 2009.
CHIOTAKIS: The BBC’s Jon Bithrey in London. Jon thank you.
BITHREY: Thank you Steve.
Marketplace is on a mission.
We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.
Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?